ALEC

Company Overview — What Does Alector, Inc. Do?

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Alector, Inc. (ALEC) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Arnon Rosenthal and employs approximately 270 people. With a market capitalization of $279M, ALEC is one of the notable companies in the Healthcare sector.

Alector, Inc. (ALEC) Stock Rating — Reduce (April 2026)

As of April 2026, Alector, Inc. receives a Reduce rating with a composite score of 32.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ALEC ranks #2,252 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Alector, Inc. ranks #262 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ALEC Stock Price and 52-Week Range

Alector, Inc. (ALEC) currently trades at $2.45. The stock gained $0.05 (2.1%) in the most recent trading session. The 52-week high for ALEC is $3.40, which means the stock is currently trading -27.9% from its annual peak. The 52-week low is $0.87, putting the stock 181.6% above its annual trough. Recent trading volume was 573K shares, suggesting relatively thin trading activity.

Is ALEC Overvalued or Undervalued? — Valuation Analysis

Alector, Inc. (ALEC) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 8.89x, versus the sector average of 2.75x. The price-to-sales ratio is 9.03x, compared to 1.66x for the average Healthcare stock.

At current multiples, Alector, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Alector, Inc. Profitability — ROE, Margins, and Quality Score

Alector, Inc. (ALEC) earns a quality factor score of 18/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -482.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -50.4% versus the sector average of -33.1%.

On a margin basis, Alector, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -777.7% (sector: -66.1%). Net profit margin stands at -705.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -78.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ALEC Debt, Balance Sheet, and Financial Health

Alector, Inc. has a debt-to-equity ratio of 33.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.83x, indicating strong short-term liquidity. Total debt on the balance sheet is $10M. Cash and equivalents stand at $77M.

ALEC has a beta of 1.50, meaning it is more volatile than the broader market — a $10,000 investment in ALEC would be expected to move 50.0% more than the S&P 500 on any given day. The stability factor score for Alector, Inc. is 17/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Alector, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Alector, Inc. reported revenue of $30M and earnings per share (EPS) of $-1.39. Net income for the quarter was $-148M. Gross margin was 100.0%. Operating income came in at $-165M.

In FY 2025, Alector, Inc. reported revenue of $21M and earnings per share (EPS) of $-1.39. Net income for the quarter was $-143M. Revenue grew -79.1% year-over-year compared to FY 2024. Operating income came in at $-156M.

In Q3 2025, Alector, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.34. Net income for the quarter was $-35M. Revenue grew -78.8% year-over-year compared to Q3 2024. Operating income came in at $-38M.

In Q2 2025, Alector, Inc. reported revenue of $8M and earnings per share (EPS) of $-0.30. Net income for the quarter was $-31M. Revenue grew -47.8% year-over-year compared to Q2 2024. Operating income came in at $-34M.

Over the past 8 quarters, Alector, Inc. has demonstrated a growth trajectory, with revenue expanding from $15M to $30M. Investors analyzing ALEC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ALEC Dividend Yield and Income Analysis

Alector, Inc. (ALEC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ALEC Momentum and Technical Analysis Profile

Alector, Inc. (ALEC) has a momentum factor score of 60/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

ALEC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Alector, Inc. (ALEC) ranks #262 out of 838 stocks based on the Blank Capital composite score. This places ALEC in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ALEC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALEC vs S&P 500 (SPY) comparison to assess how Alector, Inc. stacks up against the broader market across all factor dimensions.

ALEC Next Earnings Date

No upcoming earnings date has been announced for Alector, Inc. (ALEC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ALEC? — Investment Thesis Summary

The quantitative profile for Alector, Inc. suggests caution. The quality score of 18/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Price momentum is positive at 60/100, suggesting the trend favors buyers. High volatility (stability score 17/100) increases portfolio risk.

In summary, Alector, Inc. (ALEC) earns a Reduce rating with a composite score of 32.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALEC stock.

Related Resources for ALEC Investors

Explore more research and tools: ALEC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ALEC head-to-head with peers: ALEC vs AZN, ALEC vs SLGL, ALEC vs VMD.